Published in Cancer Res on January 15, 1993
Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci U S A (2008) 3.62
Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci U S A (2011) 2.16
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. Cancer Res (2009) 2.03
STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A (1999) 1.96
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A (2003) 1.71
Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci U S A (1996) 1.70
Production of multimeric prostate-specific membrane antigen small-molecule radiotracers using a solid-phase 99mTc preloading strategy. J Nucl Med (2007) 1.67
Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc Natl Acad Sci U S A (2001) 1.65
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
The Arabidopsis AMP1 gene encodes a putative glutamate carboxypeptidase. Plant Cell (2001) 1.52
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol (2006) 1.48
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem (2011) 1.37
NGEP, a gene encoding a membrane protein detected only in prostate cancer and normal prostate. Proc Natl Acad Sci U S A (2004) 1.25
Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg (2006) 1.23
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade. Proc Natl Acad Sci U S A (2008) 1.22
Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res (2008) 1.22
Prostate-specific membrane antigen-based imaging. Urol Oncol (2012) 1.22
Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. Mol Med (2008) 1.16
Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci (2004) 1.09
Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int J Cancer (2005) 1.07
Prostate-specific membrane antigen-based therapeutics. Adv Urol (2011) 1.06
Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther (2009) 1.05
The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. Urol Oncol (2013) 1.04
Polyamine biosynthesis impacts cellular folate requirements necessary to maintain S-adenosylmethionine and nucleotide pools. FASEB J (2009) 1.01
Bioisosterism of urea-based GCPII inhibitors: Synthesis and structure-activity relationship studies. Bioorg Med Chem Lett (2009) 1.00
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
The Maize Viviparous8 locus, encoding a putative ALTERED MERISTEM PROGRAM1-like peptidase, regulates abscisic acid accumulation and coordinates embryo and endosperm development. Plant Physiol (2008) 0.98
PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach. Proc Natl Acad Sci U S A (2002) 0.97
PET/CT Imaging and Radioimmunotherapy of Prostate Cancer. Semin Nucl Med (2011) 0.95
PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics (2015) 0.94
Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol (1998) 0.91
Intracerebroventricular administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in inflammatory pain. Mol Pain (2008) 0.90
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. J Exp Clin Cancer Res (2010) 0.90
Isolation and expression of a rat brain cDNA encoding glutamate carboxypeptidase II. Proc Natl Acad Sci U S A (1998) 0.88
Nanoparticles for Improving Cancer Diagnosis. Mater Sci Eng R Rep (2013) 0.87
Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. Cancer Res (2011) 0.87
Molecular evolution of the transferrin receptor/glutamate carboxypeptidase II family. J Mol Evol (2006) 0.86
Optimised electroporation mediated DNA vaccination for treatment of prostate cancer. Genet Vaccines Ther (2010) 0.85
NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Mol Pain (2012) 0.85
Prostate specific membrane antigen (PSMA) regulates angiogenesis independently of VEGF during ocular neovascularization. PLoS One (2012) 0.84
Transcriptional activation of the human prostatic acid phosphatase gene by NF-kappaB via a novel hexanucleotide-binding site. Nucleic Acids Res (2004) 0.84
Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology (2006) 0.83
Targeting prostate cancer cells with PSMA inhibitor-guided gold nanoparticles. Bioorg Med Chem Lett (2012) 0.82
Tumor immunotargeting using innovative radionuclides. Int J Mol Sci (2015) 0.82
Prostate-specific membrane antigen: evidence for the existence of a second related human gene. Br J Cancer (1995) 0.82
The emergence of radioimmunoscintigraphy for prostate cancer. Rev Urol (2006) 0.80
Promoter analysis of human glutamate carboxypeptidase II. Brain Res (2007) 0.80
Optimization of Acquisition time of 68Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer. PLoS One (2016) 0.79
Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen. PLoS One (2013) 0.79
Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PLoS One (2012) 0.79
Immunohistochemistry of a prostate membrane specific protein during development and maturation of the human prostate. J Anat (1997) 0.79
Prostate-specific membrane antigen is undetectable in choroidal neovascular membrane. J Carcinog (2006) 0.79
The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future. Ecancermedicalscience (2015) 0.78
Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy. J Korean Med Sci (2010) 0.77
Prostate-specific membrane antigen PET imaging and immunohistochemistry in adenoid cystic carcinoma-a preliminary analysis. Eur J Nucl Med Mol Imaging (2017) 0.77
Prostate Cancer - Old Problems and New Approaches. (Part II. Diagnostic and Prognostic Markers, Pathology and Biological Aspects). Pathol Oncol Res (1996) 0.76
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease. Br J Pharmacol (2016) 0.76
Multifunctional Envelope-Type siRNA Delivery Nanoparticle Platform for Prostate Cancer Therapy. ACS Nano (2017) 0.76
PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer. Sci Signal (2017) 0.75
Should Low Molecular Weight PSMA Targeted Ligands Get Bigger and Use Albumin Ligands for PSMA Targeting? Theranostics (2017) 0.75
68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now? Cent European J Urol (2017) 0.75
Improving the utility of prostate specific antigen (PSA) in the diagnosis of prostate cancer: the use of PSA derivatives and novel markers. Postgrad Med J (2002) 0.75
PSMA expression by microvasculature of thyroid tumors - Potential implications for PSMA theranostics. Sci Rep (2017) 0.75
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys (1998) 3.82
Antibacterial nature of prostatic fluid. Nature (1968) 3.68
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Classification of benign diseases associated with prostatic pain: prostatitis or prostatodynia? J Urol (1978) 2.74
Genetic alterations in bladder cancer. Lancet (1993) 2.73
Decreased growth of established human prostate LNCaP tumors in nude mice fed a low-fat diet. J Natl Cancer Inst (1995) 2.70
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J Clin Oncol (1993) 2.42
The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol (1997) 2.13
Molecular cloning and nucleotide sequence of full-length of cDNA coding for porcine gastrin. Proc Natl Acad Sci U S A (1982) 2.06
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections. N Engl J Med (1974) 2.05
The TNM classification of prostate cancer. Prostate Suppl (1992) 1.96
Adult urological sarcoma. J Urol (1992) 1.94
Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol (1997) 1.93
Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res (1996) 1.88
Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol (1998) 1.88
Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst (1992) 1.81
Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year follow-up. J Clin Oncol (1994) 1.78
Development and progression of clubbing and scarring in children with recurrent urinary tract infections. Radiology (1974) 1.78
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol (1995) 1.71
Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression. Nat Med (1998) 1.69
Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res (1991) 1.59
The effect of local control on metastatic dissemination in carcinoma of the prostate: long-term results in patients treated with 125I implantation. Int J Radiat Oncol Biol Phys (1991) 1.58
Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol (1998) 1.53
Prostate cancer: emerging concepts. Part I. Ann Intern Med (1996) 1.51
Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol (1992) 1.50
Simultaneous retroperitoneal, thoracic, and cervical resection of postchemotherapy residual masses in patients with metastatic nonseminomatous germ cell tumors of the testis. J Clin Oncol (1996) 1.49
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol (1996) 1.45
Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res (1995) 1.43
Effects of garlic thioallyl derivatives on growth, glutathione concentration, and polyamine formation of human prostate carcinoma cells in culture. Am J Clin Nutr (1997) 1.43
Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst (1993) 1.42
Association of the Lewis blood-group phenotype with recurrent urinary tract infections in women. N Engl J Med (1989) 1.42
Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. Urology (2001) 1.41
A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? Crit Rev Immunol (2001) 1.39
Molecular genetic alterations in superficial and locally advanced human bladder cancer. Cancer Res (1991) 1.36
Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome (2001) 1.36
Cloning of a D-type cyclin from murine erythroleukemia cells. Proc Natl Acad Sci U S A (1992) 1.35
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 1.34
Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res (1994) 1.33
Prostatic antibacterial factor. Identity and significance. Urology (1976) 1.30
Clinical and laboratory studies into the pathogenesis of malacoplakia. J Clin Pathol (1976) 1.27
Prostate-specific membrane antigen. Prostate (1997) 1.25
Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res (1989) 1.22
Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. Urology (2001) 1.22
Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. Am J Surg Pathol (1994) 1.21
Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene (2011) 1.20
E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem (1999) 1.20
Urinary tract infections in children. Part I-- Young girls with non-refluxing ureters. West J Med (1974) 1.18
Persistent membrane translocation of protein kinase C alpha during 12-0-tetradecanoylphorbol-13-acetate-induced apoptosis of LNCaP human prostate cancer cells. Cell Growth Differ (1996) 1.17
Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol (1997) 1.14
Vitamin E inhibits the high-fat diet promoted growth of established human prostate LNCaP tumors in nude mice. J Urol (1999) 1.14
Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma. Cancer (1993) 1.13
Bacteriologic and hormonal observations of the urethra and vaginal vestibule in normal, premenopausal women. J Urol (1970) 1.12
Abbott IMx evaluated for assay of prostate-specific antigen in serum. Clin Chem (1992) 1.12
Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res (1978) 1.11
The sensitivity of bladder wash flow cytometry, bladder wash cytology, and voided cytology in the detection of bladder carcinoma. Cancer (1987) 1.10
Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J Urol (1994) 1.10
Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. Cancer Genet Cytogenet (1987) 1.09
Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. J Urol (1992) 1.09
Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta (1998) 1.09
Three-day treatment of urinary tract infections. J Urol (1980) 1.08
Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. J Urol (1996) 1.08
Xanthogranulomatous pyelonephritis masquerading as occult malignancy. Urology (1978) 1.08
Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol (1997) 1.08
Reversal of radiation resistance in LNCaP cells by targeting apoptosis through ceramide synthase. Cancer Res (1999) 1.07
Allelic deletions in renal tumors: histopathological correlations. Cancer Res (1993) 1.07
Spectrum-analysis and neural networks for imaging to detect and treat prostate cancer. Ultrason Imaging (2001) 1.06
Expression of c-kit and kit-ligand in benign and malignant prostatic tissues. Histol Histopathol (2000) 1.05
The pH of prostatic fluid: a reappraisal and therapeutic implications. J Urol (1978) 1.05
Management of children with urinary tract infections: the Stanford experience. Urology (1975) 1.03
Site specific predictors of positive margins at radical prostatectomy: an argument for risk based modification of technique. J Urol (1998) 1.03
Clinical significance of repeat sextant biopsies in prostate cancer patients. Urology (1997) 1.03
A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer. J Clin Oncol (1987) 1.03
Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol (1994) 1.01
Are excretory urograms necessary in evaluating women with urinary tract infection? J Urol (1979) 1.01
Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression. J Urol (1989) 1.00
Combating prostate cancer. Sci Am (1998) 1.00
Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep (1977) 0.99
Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev (1999) 0.99